Wed, Aug 20, 2014, 1:20 PM EDT - U.S. Markets close in 2 hrs 40 mins

Recent

% | $
Quotes you view appear here for quick access.

MELA Sciences, Inc. Message Board

  • dwoods4q dwoods4q May 17, 2012 10:39 AM Flag

    MANAGEMENT DOWNSIDE

    Let me start with the fact that I like Mela, the concept, the product and the fact that they have FDA approval. As a shareholder I am concerned that the management team has so little skin [stock ownership] in the game. If Yahoo stats are correct practically nothing. Protecting a job is different than protecting/enhancing shareholder values. If they are not careful a smart fund manager could/possible is collaring the stock. The last secondary was at $4.25 aprox. management has done nothing to enhance that in fact they are presently destroying value ie lack of top PR and Financial people promoting/hyping/building the company. There is more to creating a successful company than having a product.

    Opinions

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • fish_discover_water_last fish_discover_water_last May 17, 2012 3:29 PM Flag

      "destroying value ie lack of top PR and Financial people promoting/hyping/building the company"

      They are promoting the company and building the reputation of the product in a methodical and credible way. It is the dream of every trader that the CEO spend a significant amount of their time promoting and managing the share price but I have never seen any successful company where the CEO spent his time micro-managing the share price. Gulfo is focusing on creating a long term success with the company fundamentals, not trying to maximize the share price AS HE SHOULD BE.

      Can you give an example of a company or executive in the medical device sector that has done a great job of promoting/hyping/building their company. Please give an example of a company that has been successful at this for at least 5 years.

      I get nervous when I see a management that is too focused on the share price. To me that means their focus is not in the right place for long term success.

      • 2 Replies to fish_discover_water_last
      • samhasson@sbcglobal.net samhasson May 17, 2012 5:35 PM Flag

        The ones who speak SOLELY to the "sales and marketing" aspect in terms of stock prices and ROI's lack the business experience needed to successfully navigate a company over time. Anyone seriously listening to them also lack the kind of professional and business experience needed to create real value. It's OK not to have this experience, but to speak as if you really know what you are talking about is nonsense. Sizzle is good, but only after you have the right meat product. No meat, no sizzle. Get it?

      • You are correct in your statement regarding the CEO of Mela and his present responsibilities. To name a few compannies re:marketing/financial people, lets start with the newest IPO Facebook and their current COO,look at any successful company and you will find what you are looking for.....

    • <<Goes back to that Derms 70% first time accuracy thing that you refuse to acknowledge DUMMY>>

      I'm definitely willing to acknowledge that the accuracy rate of dermatologists associated with mela might be as low as 70 percent. Maybe even lower.

    • #####################
      <You are referring to a woman who did not diagnose her own melanoma.>>

      Along with one of her colleagues also I might add
      #####################

      Yeah, the people who associate with her might not be the top dermatologists in the world.

    • <<You are referring to a woman who did not diagnose her own melanoma.>>

      Along with one of her colleagues also I might add. Goes back to that Derms 70% first time accuracy thing that you refuse to acknowledge DUMMY! 8)

    • <<I suspect that [Dr. Day and...knows] a thing or two more about Dermatology than some DIRTBAG bashers>>

      You are referring to a woman who did not diagnose her own melanoma.

    • <<Dr Day and Dr Riegal who gave it excellent reviews. And whether you think they are paid my MELA or not>>

      It's pretty common for people paid by a company to publicly say good things about the company, Captain Stupid.

      See if you can figure that one out.

    • ######################
      <<Do you realize that previously you told me he would trot them out in the wek of May 7?>>

      He did, Dr Day and Dr Riegal who gave it excellent reviews
      ####################

      Rettard, we were referring to NEW dermatologists who had begun using the thing and supposedly liked it. Day and Rigel have been trotted out by mela forevever, and at least one (probably both) were paid by mela.

    • As a shareholder I am concerned that the management team has so little skin [stock ownership] in the game


      ***********************************************************


      Little skin WITH suspicious moles.

    • <<has done nothing to enhance that in fact they are presently destroying value ie lack of top PR and Financial people promoting/hyping/building the company.>>

      Let's rethink their planned first year roll out. Gulfo has said repeatedly that he plans on just 200 units in the U.S. and 75 units in Germany for year one. I believe that he has also said in past CCs that he has already picked out where those 275 units are to be placed. His main emphasis for this first year roll out is to make sure that they get this thing right in the roll out. With the success of the first year roll out, Melafind should very much sell itself to the Derms with reviews coming in from the Derms that are using it. Therefore, I don't believe that he needs to spend the money on promoting it at this time when he is apparently not ready to ramp up mass sales.

 
MELA
2.359-0.051(-2.12%)1:14 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.